Pivotal readout

Dayvigo Korea Launch Planned

A sleep specialist reported that Dayvigo maintained improvements in insomnia outcomes for one year in SUNRISE 2, without evidence of tolerance, rebound insomnia or withdrawal symptoms after discontinuation. In SUNRISE 1, Dayvigo shortened time to sleep onset more than extended-release zolpidem in older adults.

Other studies discussed nighttime balance, next-morning driving and breathing safety. South Korea approved Dayvigo in June for adults with difficulty falling or staying asleep.

Eisai Korea plans a late-November launch and will co-promote it with SK Chemicals.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call